Search Results
Your search for 27 matches 3349 pages
Showing 2601 - 2650Oncology Meetings
May Northern New England Clinical Oncology Society Spring MeetingMay 17 • Manchester, New HampshireFor more information: www.nnecos.org Iowa Oncology Society Spring Membership ConferenceMay 17-18 • West Des Moines, IowaFor more information: www.ios-iowa.com California Breast Cancer Research...
ASCO Completes Prototype for CancerLinQ™, Marking First Demonstration of a 'Learning Health System' to Transform Cancer Care
ASCO has completed a prototype of CancerLinQ™, the Society’s groundbreaking health information technology initiative to achieve higher quality, higher value cancer care with better outcomes for patients. The prototype was shown on March 27 at the National Press Club in Washington, DC, during an...
SIDEBAR: Left-sided Adjuvant Breast Radiotherapy: A Change of Heart?
Darby and colleagues are to be congratulated for an ambitious population-based case-control study that demonstrates the impact of postoperative adjuvant ionizing radiation for early-stage breast cancer on ischemic heart disease.1 The study examined roughly 1,000 cases and 1,000 controls in Sweden...
Congress Must Reverse Devastating Budget Cuts to Cancer Care
Sandra M. Swain, MD, FACP, ASCO President, issued the following statement on April 27, 2013: “Today, out of concern for public safety, Congress provided the Federal Aviation Administration enhanced flexibility in application of sequestration related cuts, including reversal of furlough requirements ...
Early Data Promising for Concurrent Sorafenib Plus Embolization in Metastatic Liver Cancer
If sorafenib (Nexavar) and local ablation techniques are both effective in the treatment of metastatic hepatocellular carcinoma, could they deliver an even greater punch when combined? The concurrent use of interventional radiology approaches and sorafenib for metastatic hepatocellular carcinoma is ...
Sequestration's Impact on Cancer Care
On March 1, the deficit-budget mechanism known as sequestration took effect, triggering $85 billion in across-the-board cuts to most federal agencies over the remaining 7 months in fiscal year 2013. The total federal deficit reduction budget under the Budget Control Act of 2011 calls for $1.2...
Some Stage II/III HER2-positive Tumors May Be Treated with Targeted Therapy without Chemotherapy
Results from a multicenter phase II study of patients with locally advanced HER2-positive breast cancer who receive targeted therapy with trastuzumab (Herceptin) and lapatinib (Tykerb) “support the hypothesis that selected patients with HER2-positive tumors may not need chemotherapy,” investigators ...
Women at Increased Risk for Breast Cancer Should Be Offered Medications to Reduce Risk, Draft Recommendations Advise
Clinicians should engage in shared decision-making with women who are at increased risk of breast cancer about using medications, such as tamoxifen and raloxifene (Evista), to reduce risk, and should offer prescriptions to women considered at low risk for adverse effects from these medications,...
Oncology Meetings
June Molecular and Translational Oncology WorkshopJune 14-18 • Fort Myers, FloridaFor more information: www.cancereducationconsortium.org/programs_mtow.html 12th International Conference on Malignant LymphomaJune 19-22 • Lugano, SwitzerlandFor more information: www.lymphcon.ch British...
Ginger
The use of dietary supplements by cancer patients has risen significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and the...
Attention to Patient Concerns Leads to Customized Treatment and Improved Care, Explains Oncology Nurse Researcher
The Mara Mogensen Flagherty Lecture at this year’s 38th Annual Congress of the Oncology Nursing Society in Washington, DC, focused on the importance of listening to and acknowledging the individual stories of patients with cancer and survivors. Once they are adept at listening, clinicians need to...
Geriatric Factors Predict Severe Toxicity in Elderly Patients on First-line Treatment for Metastatic Colorectal Cancer
Elderly patients differ with respect to tolerance of therapy for colorectal cancer. In a study reported in Journal of Clinical Oncology, Thomas Aparicio, MD, PhD, of the University of Paris, and colleagues analyzed geriatric factors for potential association with severe toxicity, dose-intensity...
Cancer Organizations Recognize Sen. Shelby and Rep. DeLauro for Their Commitment to the Fight against Cancer
Sen. Richard Shelby (R-AL) and Rep. Rosa DeLauro (D-CT) were recognized recently by the American Society of Clinical Oncology, the American Association for Cancer Research, the Association of American Cancer Institutes, and Friends of Cancer Research for their outstanding commitment to cancer...
Study Questions Routine Use of Imaging after Treatment for Diffuse Large B-cell Lymphoma
Most relapses following treatment for diffuse large B-cell lymphoma are detected by abnormalities on physical exam, lab tests, and symptoms—not by routine imaging, according to a study presented at the ASCO Annual Meeting.1 In fact, in a prospective study assessing post-treatment outcomes of...
No Added Benefit from Radiotherapy after Lumpectomy/Tamoxifen in Older Women
Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9343 “confirms and extends the earlier report that in women age ≥ 70 years with clinical stage I, [estrogen receptor (ER)]-positive breast cancer treated with lumpectomy followed by tamoxifen, irradiation adds no significant benefit in...
Trametinib in Unresectable or Metastatic Melanoma with BRAF V600E or BRAF V600K Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, trametinib (Mekinist) was approved by...
Oncology Meetings
June 2nd International Breakthrough Breast Cancer Conference– Triple Negative Breast CancerJune 26-28 • London, United KingdomFor more information: www.breakthroughconference.org.uk MASCC/ISOO 2013 International Cancer Care SymposiumJune 27-29 • Berlin, GermanyFor more information: mascc.kenes.com ...
Vitamin D and Cancer: A Uniform Dose Is Unlikely to Fit All Patients
Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, Chief of the Integrative Medicine Service and Laurance S. Rockefeller Chair in Integrative Medicine at Memorial Sloan-Kettering Cancer Center, New York. The Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center...
Dabrafenib for Unresectable or Metastatic Melanoma with BRAF V600E Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, dabrafenib (Tafinlar) was approved for ...
Identification of Oncogenic Mutations in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
Among the hematologic cancers for which molecular causes remain unclear are chronic neutrophilic leukemia and atypical (BCR-ABL1–negative) chronic myeloid leukemia. Both disorders currently are diagnosed on the basis of neoplastic expansion of granulocytic cells and exclusion of genetic factors...
Similar Short-term Outcomes with Laparoscopic vs Open Surgery for Rectal Cancer
As recently reported in Lancet Oncology by Martijn H.G.M. van der Pas, MD, of VU University Medical Center, Amsterdam, and colleagues, the phase III COLOR II trial has shown that laparoscopic surgery can produce similar safety outcomes, resection margins, and completeness of resection compared with ...
Reducing Unnecessary and High-dose Pediatric CT Scans Could Cut Future Cancers by More than Half
A study examining trends in x-ray computed tomography (CT) use in children in the United States has found that reducing unnecessary scans and lowering the doses for the highest-dose scans could lower the overall lifetime risk of future imaging-related cancers by 62%. The research was published...
Expert Point of View: Electra D. Paskett, PhD
Formal discussant Electra D. Paskett, PhD, Professor of Medicine at The Ohio State University, was enthusiastic about these trial results and the potential of visual inspection with acetic acid screening, as well as low-cost human papillomavirus (HPV) screening to save lives in the developing...
Shiitake Mushroom
The use of dietary supplements by patients with cancer has increased significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and...
Oncology Meetings
July WIN 2013 Symposium: Personalized Cancer Therapy: From Innovation to ImplementationJuly 10-12 • Paris, FranceFor more information: www.winsymposium.org 12th International Congress on the Future of Breast CancerJuly 18-20 • Huntington Beach, CaliforniaFor more information:...
Outcomes with Adjuvant Trastuzumab in HER2-positive Breast Cancer Not Affected by PTEN Status
PTEN is a negative regulator of PI3K/AKT signaling. PI3K/AKT signaling can be activated by HER2, and it has been hypothesized that alteration in this pathway may affect sensitivity to trastuzumab (Herceptin). Preclinical data and some of the limited available clinical data suggest that loss or...
Measurement of Circulating Tumor DNA Shows Promise in Monitoring Metastatic Breast Cancer
Management of metastatic breast cancer requires monitoring of tumor burden to assess response to treatment, and there is a need for biomarkers that can measure tumor burden with high sensitivity and specificity. Assays measuring serum cancer antigen (CA) 15-3 and circulating tumor cells have been...
Molecular Landscaping of Acute Myeloid Leukemia: Are We Relearning the Past or Informing the Future?
Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease.1 This concept has been supported by more than 4 decades of studies showing distinct outcomes of subsets of patients that differ in age, disease type (primary vs secondary vs therapy-related), and cytogenetic and...
Genomic and Epigenomic Characterization of Acute Myeloid Leukemia
In a study by the Cancer Genome Atlas Research Network reported in The New England Journal of Medicine, genomes of 200 adult cases of de novo acute myeloid leukemia (AML) were analyzed by whole-genome sequencing (n = 50) or whole-exome sequencing (n = 150) to identify mutations and relationships...
Pain Is More Prevalent and Severe in Men with Metastatic Disease and Use of Docetaxel
Men who have metastatic castration-resistant prostate cancer and have used docetaxel reported a higher prevalence and greater severity of pain than docetaxel-naive patients, according to results of an anonymous survey conducted at five comprehensive cancer centers in the Prostate Cancer Clinical...
Oncology Meetings
July 14th International Lung Cancer CongressJuly 25-27 • Huntington Beach, CaliforniaFor more information: www.gotoper.com/conferences Up Close and Personalized: The 2nd International Congress on Personalized MedicineJuly 25-28 • Paris, FranceFor more information: www.upcp.org Multidisciplinary...
Management of Anaplastic Oligodendroglial Tumors
Pearls in Neuro-oncology is guest edited by Tracy Batchelor, MD, Director, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, and Professor of Neurology, Harvard Medical School, Boston. The series is intended to provide the practicing oncologist with guidance in managing...
Critically Ill Hematology Patients Admitted to ICU Have Good Survival, Disease Control, and Quality of Life
A large prospective multicenter cohort study in France and Belgium, reported by Elie Azoulay, MD, of Saint-Louis Hospital, Paris, and colleagues from the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique,1 has shown that critically ill patients with hematologic malignancies...
New Research Presented in Breast, Gastric, Esophageal Cancers, Melanoma, and Multiple Myeloma, plus Supportive Care
Attendees at the ASCO Annual Meeting are faced with a major challenge of trying to attend as many important sessions as they can over a 4-day period. Our challenge is to feature the major news in The ASCO Post. In addition to our regular comprehensive coverage of key presentations, the following...
Why Is Stem Cell Transplant So Underused in Follicular Lymphoma?
Follicular lymphoma is the second most common subtype of non-Hodgkin lymphoma (NHL) in the United States. Of the nearly 70,000 new cases of NHL anticipated in 2013,1 approximately 7,000 to 13,000 (10%–19%) will be follicular lymphoma, by recent estimates.2-5 For many years, the median overall...
Expert Point of View: Hedy Lee Kindler, MD
Hedy Lee Kindler, MD, Associate Professor of Medicine at the University of Chicago, the invited discussant of three of these presentations, emphasized the persistent lethality of advanced pancreatic cancer. She predicted that within this decade, pancreatic cancer will become the second leading...
Some Successes, Some Failures Reported in Research and Treatment of Pancreatic Cancer
The challenge of treating pancreatic cancer inched forward with studies reported at the 2013 ASCO Annual Meeting, though some important studies proved disappointing. Nab-paclitaxel Improves Overall Survival In treatment-naive metastatic patients, the addition of nanoparticle albumin-bound...
Oncology Meetings
August Hematology and Medical Oncology Best PracticesAugust 15-22 • Arlington, VirginiaFor more information: www.gwumc.edu/cehp/hemoncbestpractices/ Best of ASCO® Los AngelesAugust 16-17 • Los Angeles, CaliforniaFor more information: boa.asco.org ISEH – Society for Hematology and Stem Cells 42nd...
Policy Update Aims to Advance Tobacco Cessation and Control Worldwide
In response to scientific advances and the evolving regulatory and policy environment, ASCO recently released an update to its 2003 policy statement on tobacco cessation and control. The statement reviews advancements that have been made since 2003 and outlines a refined set of recommendations...
Age Not Linked to Recurrence in Observation or Trastuzumab Groups with HER2-positive Breast Cancer
Available data suggest that younger age is an independent risk factor for disease recurrence and death in women with breast cancer. However, there has not been adequate study of the interaction of age with human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. In an analysis ...
Low-dose CT Screening for Lung Cancer: Details of First Round of Screening in National Lung Screening Trial
The National Lung Screening Trial found that 3 years of annual screening with low-dose helical computed tomography (CT) reduced lung cancer mortality compared with chest radiography in older persons who were heavy smokers.1 The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial also...
Crizotinib Improves Progression-free Survival vs Pemetrexed or Docetaxel in Advanced ALK-positive NSCLC
In a phase III trial reported by Alice T. Shaw, MD, PhD, a thoracic oncologist at Massachusetts General Hospital, Boston, and colleagues in The New England Journal of Medicine, crizotinib (Xalkori) improved progression-free survival compared with standard chemotherapy in previously treated patients ...
Ibrutinib Produces High Response Rate in Patients with Refractory Mantle Cell Lymphoma
Ibrutinib is a first-in-class oral covalent inhibitor of Bruton’s tyrosine kinase, a mediator of the B cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. As reported in The New England Journal of Medicine, Michael L. Wang, MD, of The University of Texas MD Anderson...
Oncologists Speak Out Against the High Cost of Cancer Drugs
That the United States spends twice as much on health care than other industrialized countries—about $2.8 trillion in 2012—without reaping appreciably better outcomes1 is not news. The topic has been dissected on the front pages of leading newspapers for years and was the subject of the entire...
Expert Point of View: Tim Maughan, MD
Maintenance treatment with capecitabine plus bevacizumab can be considered in clinical practice, according to Tim Maughan, MD, Professor of Clinical Oncology at Oxford University in the United Kingdom, who discussed CAIRO3 at the session. He said that approximately 60% of patients with metastatic...
Ginseng
Guest Editor Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, Chief of the Integrative Medicine Service and Laurance S. Rockefeller Chair in Integrative Medicine at Memorial Sloan-Kettering Cancer Center, New York. The Integrative Medicine Service at Memorial Sloan-Kettering...
Oncology Meetings
September Georgia Society of Clinical Oncology 2013 GASCO Annual MeetingSeptember 6 • Atlanta, GeorgiaFor more information: www.gasco.us SGI Summit Turkey 2013: Innovations in Obstetrics and GynecologySeptember 6-8 • Istanbul, TurkeyFor more information: www.sgiturkey2013.org/ Breast Cancer...
American Ginseng Improves Cancer-Related Fatigue
In a collaborative phase III trial of the North Central Cancer Treatment Group and Mayo Clinic (N07C2) reported in Journal of the National Cancer Institute by Debra L. Barton, RN, PhD, AOCN, FAAN, of the Mayo Clinic and colleagues, patients with cancer-related fatigue were treated with Wisconsin...
Integrating Genomic Sequencing Into Clinical Care
Although the price of next-generation genomic sequencing is coming way down, making it available to more people interested in determining their risk for disease, figuring out how to interpret the results and applying that information in the routine medical care of individual patients remains a...
Pemetrexed Maintenance in PARAMOUNT: Continuation Proves to Be a Strong Option for Advanced NSCLC, Although Not a Mandate
The PARAMOUNT trial1 represents an important landmark study of continuation maintenance therapy with pemetrexed (Alimta). While maintenance therapy gained a toehold in routine management of advanced non–small cell lung cancer (NSCLC) several years ago, the first trials that demonstrated a...
